Engaging with Bispecific T-Cell Engagers
Last Updated: May 16, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 08/10/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 08/10/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 08/10/2025
Example SOPs and Documents: On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers
Last Updated: 08/10/2025
PQI
PQI
PQI in Action
PQI
PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol
Author: Sharon Zhong, PharmD, BCOP
Last Updated: 08/10/2025
PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC
Author: Aubrey Lasko, PharmD, BCOP
Last Updated: 08/10/2025
PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2
Author: Johns Hopkins, MD | The University of Texas MD Anderson Cancer Center, TX
Last Updated: 08/10/2025
PQI: Bone Health and the Cancer Patient
Author: Nina DiPierro Pharm.D. BCOP, Florida Cancer Specialists and Research Institute | Farishta Manzoor, PharmD, Hartford HealthCare Cancer Institute
Last Updated: 08/10/2025